Pfizer Inc (PFE): Today's Featured Drugs Loser

Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.5%. By the end of trading, Pfizer fell 12 cents (-0.5%) to $22.66 on average volume. Throughout the day, 31.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 34.5 million shares. The stock ranged in price between $22.58-$22.98 after having opened the day at $22.69 as compared to the previous trading day's close of $22.78. Other company's within the Drugs industry that declined today were: Savient Pharmaceuticals ( SVNT), down 18.3%, Idera Pharmaceuticals ( IDRA), down 11.8%, Amyris ( AMRS), down 7.8%, and NuPathe ( PATH), down 7.7%.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $172.61 billion and is part of the health care sector. The company has a P/E ratio of 20.6, above the average drugs industry P/E ratio of 17.9 and above the S&P 500 P/E ratio of 17.7. Shares are up 5.3% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, iBio ( IBIO), up 27%, CytRx Corporation ( CYTR), up 15.6%, NeurogesX ( NGSX), up 14.7%, and Protalix BioTherapeutics ( PLX), up 13.3%, were all gainers within the drugs industry with Amgen ( AMGN) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).